Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

REHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that its Board of Directors has declared a cash dividend of $0.17 (approximately NIS 0.50) per share on the Company’s ordinary shares (totaling approximately $9.8 million). The cash dividend will be payable on September 17, 2026, to shareholders of record at the close of business on August 27, 2026. The dividend payment is consistent with the Company’s dividend policy.

“Based on the Company’s record-high financial results for the first six months of 2026 and our solid cash position, we are pleased to announce a cash dividend to be paid to our shareholders,” said Amir London, Kamada’s Chief Executive Officer. “This dividend payment reinforces our confidence in the Company’s business prospects and liquidity to continue investing in our commercial growth and securing new business development and M&A transactions, while also paying dividend to our shareholders. I would like to thank our shareholders for their continued support and trust in Kamada.”